A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib) Relationships among Protein Conformation, Inhibitor Off-Rate, and Receptor Activity in Tumor Cells

Department of Computational, Analytical and Structural Sciences, GlaxoSmithKline, Inc., Research Triangle Park, North Carolina 27709, USA.
Cancer Research (Impact Factor: 9.33). 10/2004; 64(18):6652-9. DOI: 10.1158/0008-5472.CAN-04-1168
Source: PubMed


GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clinical development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2. We determined the crystal structure of EGFR bound to GW572016. The compound is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously. Surprisingly, we found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa). Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation. We evaluated the duration of the drug effect after washing away free compound and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain. The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells. The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.

14 Reads
  • Source
    • "Recently we reported an effective in silico screening method to isolate candidates that inhibit HBV replication [8]. Besides our study, several researchers have successfully discovered protein targets implicated in various diseases [9] [10], resulting in fierce competition among pharmaceutical companies and other organizations to discover drug-candidate compounds that inhibit or activate these protein targets [11]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antiviral therapy for chronic hepatitis B that uses nucleos(t)ide analogue is considered effective. However, most drugs of this class frequently result in viral relapse after cessation of therapy as well as the emergence of resistance, thereby limiting their clinical use. In order to increase the therapeutic efficiency of chronic hepatitis B treatments, it is important to survey novel (chemical) reagents targeting other stages of the viral replication process. The aim of this study was to identify novel capsid inhibitor candidates using in silico screening. We discovered four such candidates that decreased the levels of HBV DNA and HBsAg in vitro. These four capsid inhibitor candidates did not induce cell toxicity even at high concentrations. Results from docking simulation showed that the candidates bounded with high affinity with the capsid protein hydrophobic binding site. Identifying direct acting HBV core protein inhibitors increases the likelihood that novel medicines can be developed that allows the combination of novel anti-viral drugs and nucleos(t)ide analogue or interferon for HBV treatment. Copyright © 2015. Published by Elsevier Inc.
    Biochemical and Biophysical Research Communications 06/2015; 463(4). DOI:10.1016/j.bbrc.2015.06.077 · 2.30 Impact Factor
  • Source
    • "Epidermal growth factor receptors are family of receptor tyrosine kinases that play a crucial rule in cell growth regulation and survival (Olayioye et al., 2000); they are highly expressed in a number of human tumors as breast cancer, colon, prostate and ovarian cancer, thus considered as attractive targets for the design and development of new anticancer active agents. It was also reported that quinazoline derivatives have a potent inhibitory activity against EGFR (Barlesi et al., 2005; Burris et al., 2005; Hennequin et al., 2002; Kopper, 2008; Wood et al., 2004); hence, docking the best active compounds 2c,d and 3a,f into ATP binding site of EGFR was performed to explore the possible interactions and amino acid binding for these compounds with EGFR. "
    [Show abstract] [Hide abstract]
    ABSTRACT: 6,8-Dibromo-2-(4-chlorophenyl)-quinazolin-4- one linked directly to oxadiazole 5, pyrazole 6 or through amide linkage to thiazolidinone 2a–d and 3a–h were synthesized; their chemical structures were confirmed by spectral and elemental analyses. Their anti-breast cancer activity was evaluated against human breast cancer cell line (MCF-7) using resazurin reduction method and doxorubicin as a reference drug. Linking quinazolin-4-one scaffold to oxadiazole or pyrazole gave compounds 5 and 6 with a closely similar activity as doxorubicin; their IC50 was 23, 22 and 22 nmol/ml, respectively; however, the hybridization of quinazolin-4-one with thiazolidinone gave much better activity than doxorubicin. The most active compounds of the hybrid molecules between quinazolin-4- one and thiazolidinone are 2c,d and 3a,f. Their IC50 range was (3–9 nmol/ml). In an attempt to explore the mode of action of the best active compounds, docking on the ATP binding site of EGFR was performed. In vitro screening of these four compounds against EGFR tyrosine kinases showed inhibitory activity range 54–77.2 %.
    Medicinal Chemistry Research 03/2015; 24(7). DOI:10.1007/s00044-015-1357-1 · 1.40 Impact Factor
  • Source
    • "The biological consequences of the binding of TKIs with EGFR family members are poorly understood, and several researchers are currently examining the different TKIs interactions within the human kinome [156]. In addition, it has been described that TKIs can interact with different dimerization complexes with active or inactive forms of EGFRs [157] [158] [159]. Also, TKIs can modify the amount of EGFR family ligands [122]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: An increasing number of tumors, including breast cancer, overexpress proteins of the epidermal growth factor receptor (EGFR) family. The interaction between family members activates signaling pathways that promote tumor progression and resistance to treatment. Human epidermal growth factor receptor type II (HER2) positive breast cancer represents a clinical challenge for current therapy. It has motivated the development of novel and more effective therapeutic EGFR family target drugs, such as tyrosine kinase inhibitors (TKIs). This review focuses on the effects of three TKIs mostly studied in HER2-positive breast cancer, lapatinib, gefitinib and neratinib. Herein, we discuss the mechanism of action, therapeutic advantages and clinical applications of these TKIs. To date, TKIs seem to be promising therapeutic agents for the treatment of HER2-overexpressing breast tumors, either as mono-therapy or combined with other pharmacological agents.
    American Journal of Cancer Research 11/2015; 5(9):2531-2561. · 4.17 Impact Factor
Show more

Preview (2 Sources)

14 Reads
Available from